Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.
/ 2 items
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.